Preferred Label : AMP KRAS Vaccine ELI-002;
NCIt synonyms : Amphiphile mKRAS Peptides/Amp CpG-7909 ELI-002; Vaccine ELI-002; mKRAS Vaccine ELI-002;
NCIt definition : A peptide-based cancer vaccine composed of the adjuvant Amphiphile (Amph; AMP)-CpG-7909,
which is a lipid-conjugated immune-stimulatory oligonucleotide, admixed with Amph
modified Kirsten Rat Sarcoma (KRAS) mutated peptides, which contain a mixture of lipid-conjugated
peptide-based antigens, with potential immunostimulatory and antitumor activities.
Upon subcutaneous administration of the AMP KRAS vaccine ELI-002, the lipid moieties
bind to tissue albumin and the complex is delivered to and accumulates in the lymph
nodes where it is taken up by antigen presenting cells (APCs), primarily dendritic
cells (DCs). This may stimulate the host immune system to mount a cytotoxic T-cell
lymphocyte (CTL)-mediated immune response against KRAS/neuroblastoma ras viral oncogene
homolog (NRAS)-expressing tumor cells. KRAS and NRAS, tumor-associated antigens (TAAs)
that are involved in the RAS/mitogen-activated protein kinase (MAPK) signaling pathway,
are overexpressed on a variety of tumor cell types and play key role in tumor cell
proliferation. The CpG-based adjuvant may enhance the mutated KRAS T cell-specific
immune response. ELI-002 2P contains two KRAS mutated Amph-peptides, including Amph-G12D
and Amph-G12R. ELI-002 (ELI-002 7P) contains seven KRAS mutated Amph-peptides (Amph-Peptide
7), including G12D, G12R, G12V, G12A, G12C, G12S and G13D.;
Molecule name : ELI-002; ELI 002;
NCI Metathesaurus CUI : CL1662063;
Origin ID : C179231;
UMLS CUI : C5555547;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
